STRATEC REPORTS DEFINITIVE RESULTS FOR FIRST NINE MONTHS OF 2025

• Despite supply chain-induced interruption to production, consolidated sales at constant currency up 2.5% (nominal: +1.5%) to € 175.6 million in 9M/2025 (9M/2024: € 173.0 million)
• Scale effects and higher earnings contributions from the realization of high-margin development sales are expected to drive significantly more dynamic earnings momentum in the fourth quarter of 2025
• Ongoing great momentum and strong demand for system solution development cooperations; new partnerships initiated
• 2025 guidance: sales at constant currency expected at around previous year’s level with adjusted EBIT margin at lower end of forecast corridor of 10.0% to 12.0%

Birkenfeld, November 7, 2025

STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) today announced its financial results and major events for the period from January 1, 2025 to September 30, 2025 with the publication of its Quarterly Statement 9M|2025.

KEY FIGURES ¹

€ 000s	9M/2025	9M/20242	Change	Q3/2025	Q3/20242	Change
Sales	175,588	172,958	+1.5% (cc: +2.5%)	56,998	60,267	-5.4% (cc: -3.4%)
Adj. EBITDA	24,235	26,623	-9.0%	8,165	9,197	-11.2%
Adj. EBITDA margin (%)	13.8	15.4	-160 bps	14.3	15.3	-100 bps
Adj. EBIT	12,824	15,149	-15.3%	4,337	5,269	-17.7%
Adj. EBIT margin (%)	7.3	8.8	-150 bps	7.6	8.7	-110 bps
Adj. consolidated net income	7,104	8,434	-15.8%	2,126	2,831	-24.9%
Adj. earnings per share (€)	0.58	0.69	-15.9%	0.17	0.23	-26.1%
Earnings per share (€)	0.34	0.39	-12.8%	0.13	0.06	+116.7%

Adj. = adjusted / bps = basis points / wb = constant currency

¹ To facilitate comparison, figures for 2025 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses). The figures for 2024 have additionally been adjusted to exclude one-off personnel expenses of € 1.7 million in connection with the departure of a member of the Board of Management.
² Restated pursuant to IAS 8.

“Despite a challenging environment, STRATEC can report consolidated sales growth for the first nine months of 2025. Driven by trade policy tensions, temporary interruptions are apparent in the supply chains for some of our system lines. These particularly relate to the supply situation for a specific type of magnet. This already led to delays in planned system deliveries in the third quarter. Production volumes will also be adversely affected by this factor in the fourth quarter of 2025, meaning that we only expect to be able to make up for most of these delivery backlogs in the first quarter of 2026. As a result, we recently made a slight adjustment to our sales guidance for 2025. Despite the lower benefits of scale now expected and continuing unfavorable exchange rates, it is nevertheless pleasing to note that we can confirm the lower end of the forecast corridor for the adjusted EBIT margin. This confirms the program of efficiency measures we have initiated. The renewed increase in demand and our customers’ greater willingness to engage in new development partnerships in the area of systems give us additional confidence. Our power of innovation and great competitiveness enable us to react flexibly to market changes and draw on those opportunities arising in a demanding climate”, comments Marcus Wolfinger, Chief Executive Officer of STRATEC SE.

BUSINESS PERFORMANCE
STRATEC increased its consolidated sales year-on-year by 2.5% on a constant-currency basis (nominal: +1.5%) to € 175.6 million in the first nine months of 2025 (9M/2024: € 173.0 million). Systems sales at constant currency virtually matched the previous year’s level. Alongside start-up curves for new product launches remaining flatter than usual, the third quarter also brought supply chain interruptions in connection with trade policy tensions and thus delivery backlogs with some system lines. By contrast, the stabilization in demand for system lines which had seen disruptions in the wake of the COVID-19 pandemic continued apace. Constant-currency sales with Service Parts and Consumables fell slightly short of the previous year’s high figure. In the third quarter of 2025, this division felt the effects of volatile order behavior and logistics optimization measures taken by customers to account for changeable global tariff restrictions. Conversely, sales with Development and Services showed double-digit percentage growth, benefiting from a high volume of development activities and numerous customer projects currently underway.

Adjusted EBIT amounted to € 12.8 million in the first nine months of 2025 (9M/2024: € 15.1 million). Compared with the previous year, the adjusted EBIT margin thus fell by 150 basis points from 8.8% to 7.3%. This was particularly due to product mix effects within the Systems operating division, as well as to a temporary dip in the share of high-margin Service Parts and Consumables in the third quarter of 2025. The margin performance was additionally held back by negative exchange rate effects.

Adjusted consolidated net income stood at € 7.1 million in the first nine months of 2025, compared with € 8.4 million in the previous year. Here, STRATEC witnessed a year-on-year improvement in its net financial expenses and an increase in its adjusted tax rate. Adjusted earnings per share (basic) amounted to € 0.58 (9M/2024: € 0.69).

The key earnings figures for the first nine months of 2025 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses). A reconciliation of the adjusted figures with those reported in the consolidated statement of comprehensive income can be found in the Quarterly Statement 9M|2025 also published today.

FINANCIAL GUIDANCE
As already communicated in the announcement published on October 30, 2025, STRATEC expects to witness temporary interruptions to the supply of input materials for some system lines in the fourth quarter of 2025. In particular, in connection with trade policy tensions supply chain interruptions have arisen for a specific type of magnet with impurities relating to export-restricted rare earths (share of rare earths in affected production batch: 0.1%). Against this backdrop, delivery backlogs already arose for system deliveries in the third quarter of 2025. STRATEC does not expect to receive sufficient quantities of input materials to make up for these delivery backlogs or for the production volumes originally planned for the fourth quarter of 2025. Furthermore, global tariff conflicts are leading to higher fluctuations in customers’ order behavior and to associated logistics optimization measures. These particularly affect the Service Parts and Consumables division. In view of these factors, on October 30, 2025 the Board of Management decided to adjust its sales guidance for the 2025 financial year. STRATEC now expects its consolidated sales at constant currency to approximately match the previous year’s figure. Despite the lower sales base hereby forecast and negative currency items, STRATEC confirmed the lower end of the forecast corridor of around 10.0% to 12.0% for its adjusted EBIT margin. The expected intra-year rise in profitability in the fourth quarter of 2025 is attributable to benefits of scale, efficiency measures, and higher earnings contributions from the realization of high-margin development sales.

Based on updated planning, STRATEC assumes that its investments in property, plant and equipment and intangible assets in the 2025 financial year will fall slightly short of the originally forecast range of a total of 8.0% to 10.0% of sales (2024: 7.1%).

PROJECTS AND OTHER DEVELOPMENTS
Together with its partners, in the third quarter of 2025 STRATEC once again made further scheduled progress with numerous development projects and paved the way for additional cooperation agreements. The increasing willingness shown by customers in recent months to reach decisions concerning cooperations in the systems development business continued. Among other aspects, STRATEC has observed growing demand for lifecycle transfers. Furthermore, customers are increasingly looking for partners who are able to assume full responsibility for design, production, and delivery for the entire product lifecycle. The background to this development involves reorganization measures and M&A activities at customers, as well as their strategic focus on products already established in the market. These factors are supplemented by changed market conditions and growing requirements in terms of materials procurement. Against this backdrop, STRATEC recently initiated a partnership for a well-established high-throughput product in the field of molecular diagnostics.

The third quarter of 2025 also saw the market launch of the P780, a next-generation analyzer system offered under the Diatron brand in the field of clinical chemistry. To address a wide range of target customers, the P780 was developed for medium to large laboratories, offering an innovative and scalable solution characterized by great reliability.

DEVELOPMENT IN PERSONNEL
Including personnel hired from temporary employment agencies and trainees, the STRATEC Group had a total of 1,420 employees as of September 30, 2025 (previous year: 1,462 employees). This corresponds to a reduction of 2.9% compared with the previous year’s reporting date and is to be viewed in connection with the continuation in 2025 of the measures taken to enhance efficiency and improve earnings.

QUARTERLY STATEMENT 9M|2025
The Quarterly Statement 9M|2025 of STRATEC SE has been published on the company’s website at www.stratec.com/financial_reports.

CONFERENCE CALL AND AUDIO WEBCAST
To mark the publication of the definitive results for the first nine months of 2025, STRATEC will be holding a conference call in English at 2.00 p.m. (CET) today, Friday, November 7, 2025.

You will receive the dial-in data (telephone number, password + individual PIN) following brief registration at the following link: www.stratec.com/registration

The conference call will also be available at the same time as an audio webcast at http://www.stratec.com/audiowebcast20251107 (brief registration required). Please note that no questions can be submitted via the audio webcast. Clicking this link also enables you to follow or download the slide presentation.

ABOUT STRATEC
STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software, and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler, CFA | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com

Ad-hoc Disclosure of Inside Information Pursuant to Article 17 Regulation (EU)
No. 596/2014

 

Pentixapharm significantly reduces projected loss for financial year 2025

 

Berlin, Germany, November 6, 2025 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech developing radiopharmaceuticals, announces that its projected consolidated loss for the financial year 2025, based on an updated projection, will be significantly lower than previously anticipated.

 

The company now forecasts an annual loss of approximately €18 million instead of the previously expected €23.5 million. The forecasts for the separate financial statements of Pentixapharm Holding AG as well as the expected cash reach until the first quarter of 2027 remain unchanged.

 

The revised forecast reflects the realignment of the clinical development programs initiated in May 2025. In particular, the earlier-than-planned termination of the slow-recruiting diagnostic study in marginal zone lymphoma and optimized study design have lowered clinical spending more significantly than initially expected. With the sharpened focus on the clinically most value driving programs implemented in October 2025, the company is continuing to execute on its optimization course.

 

 About Pentixapharm

Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops precision diagnostics and therapeutics in oncology and cardiology to transform patient care. Its clinical pipeline is anchored by CXCR4-targeted PET-CT programs, including a Phase 3-ready candidate for the improved diagnosis of hypertensive patients with primary aldosteronism, which is intended to enable targeted treatment of the underlying causes of hypertension. CXCR4-based developments also include pioneering therapeutic programs in hematological cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. Complemented by CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain, Pentixapharm is poised to deliver meaningful patient benefit and sustainable growth in one of the fastest-growing areas of precision medicine.

 

Pentixapharm Investor and Media Contact

ir@pentixapharm.com

Bad Neustadt a. d. Saale | 6 November 2025

RHÖN-KLINIKUM AG closes third quarter of 2025 with solid results
 

• Revenues up by 7.8% while patient numbers increased by 2.5%
   
• EBITDA declined slightly to EUR 71.8 million due to the end to relief from the legislator for higher energy prices and challenges in cost trends
   
• Consolidated profit of EUR 25.1 million with a decrease in finance result keeps equity ratio stable
   
• Board of Management focused on managing  the Group in a consistent, flexible and sustainable manner at times of a difficult financial and economic environment for hospitals in Germany

RHÖN-KLINIKUM AG closed the third quarter of 2025 once again with an increase in revenues of 7.8% to EUR 1,262.1 million (9M 2024: EUR 1,171.1 million). From January to September 2025 a total of 705,830 patients were treated on an inpatient and outpatient basis in the Group’s hospitals and medical care centres, 2.5% more compared with the same period of the previous year (9M 2024: 688,787). At EUR 71.8 million, EBITDA was below the previous year’s level (9M 2024: EUR 75.1 million). Consolidated profit decreased to EUR 25.1 million (9M 2024: EUR 30.4 million). The equity capital ratio stands at 71.9% (FY 2024: 71.4%).

Despite stable performance indicators, consolidated profit was impacted by the end to reimbursements by the legislator for higher energy expenditures recognised in the amount of EUR 13 million in the previous year as well as the continuing downward trend in interest rates. Moreover, the first nine months of financial year 2025 continued to be characterized by indirect effects of geopolitical risks and resulting high purchasing prices, tariff increases and political developments associated with the hospital reform in Germany.

Dr. Stefan Stranz, member of the Board of Management of RHÖN-KLINIKUM AG: “Our Company’s performance continues to be stable, particularly as compared with the overall demanding situation of hospitals and the sector in Germany. Our high equity capital ratio underscores the Company’s sound financial structure.”   

Dr. Gunther K. Weiß, member of the Board of Management of RHÖN-KLINIKUM AG: “What the hospitals need from the government are clear statements on where the hospital sector is heading in future and on urgently needed solutions to key issues of the sector, such as structural underfunding and excessive red tape. These points have not yet been sufficiently addressed in the current drafts of the Hospital Reform Adjustment Act (Krankenhausreformanpassungsgesetz, KHAG).”

Outlook for 2025 confirmed

For the current financial year, the Group expects revenues of EUR 1.7 billion within a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), a level of between EUR 110 million and EUR 125 million is expected. In addition to the financial numbers, RHÖN-KLINIKUM AG also takes account of the non-financial performance indicators of number of cases and cost weights in the management of the Company. These are expected to see a moderate increase compared with the previous year.

This forecast reflects the heightened regulatory interference by the German legislator and the political implementation of the necessary hospital reform.

The Group notes that the outlook is subject to considerable uncertainties in connection with the numerous global crises resulting among other things in higher prices and supply chain issues, as well as any further regulatory measures impacting the remuneration structure for medical services in 2025.
 

The Quarterly Statement for Q3 2025 is published on the Internet.

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 913,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,700 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with ASKLEPIOS are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com

Contact:

RHÖN-KLINIKUM AG | Head of Group Finance
Norman Dittes | T. +49 9771 65-12210 | norman.dittes@rhoen-klinikum-ag.de
 

RHÖN-KLINIKUM AG | Corporate Communications
Heike Ochmann | T. +49 9771 65-12130 | heike.ochmann@rhoen-klinikum-ag.com
 

RHÖN-KLINIKUM AG | Schlossplatz 1 | 97616 Bad Neustadt a. d. Saale | Germany

PRESS RELEASE

Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma

• Evidence of clinical activity observed in Cohort 8, including stringent complete remission in two patients from Cohort 8
• HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed in Cohort 8

• R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST)

Ladenburg, Germany, 6 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that HDP-101 (INN: pamlectabart tismanitin), the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma, shows further clinical activity in Cohort 8 at a dose level of 140 µg/kg. These findings are highlighted by observed stringent complete remissions in two patients from Cohort 8.

Seven patients were evaluated in Cohort 8, and all patients demonstrated a favorable safety and tolerability profile throughout. Encouraging signs of clinical activity have also emerged. Four patients showed biological activity of HDP-101 (INN: pamlectabart tismanitin), with one partial response, one very good partial response and two stringent complete remissions (sCR). For sCR, no tumor cells are detectable in blood and bone marrow.

Dr András Strassz, Chief Medical Officer at Heidelberg Pharma, said: “We are very delighted by the data seen so far. Several patients across different cohorts have shown objective responses and promising anti-tumor activity. Observing two stringent complete remissions is an encouraging validation of our therapeutic approach. We have previously seen complete remission in one patient from Cohort 5, but in Cohort 8 onset of the response was more rapid. These findings further strengthen our confidence in the therapeutic potential of HDP-101 in heavily pretreated patients with relapsed or refractory multiple myeloma, and we are now progressing with Cohort 9 with an escalated dose of 175 µg/kg to continue its clinical evaluation.”

Heidelberg Pharma’s Phase I/IIa clinical study is a non-randomized, open-label, dose escalation trial actively enrolling patients with relapsed or refractory multiple myeloma or other BCMA-expressing plasma cell disorders. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HDP-101 (INN: pamlectabart tismanitin) in this patient population.

Heidelberg Pharma will discuss these findings in an R&D webinar on 11 November 2025 at 05:00 pm CET (11:00 am ET; 08:00 am PST), for investors, analysts, and media.

The webinar will feature presentations by the Heidelberg Pharma management team and Key Opinion Leader (KOL) Professor Marc-Steffen Raab, Head of the Myeloma Center at the University Hospital Heidelberg and clinical investigator of the study.

For further information on the R&D webinar, or to register your attendance, please use the link below:

https://us06web.zoom.us/webinar/register/WN_AG_mESPaT-aSsm8_O2DllA

A recording of the R&D webinar will be accessible via the press & investor section of the Company website after the event.

About Heidelberg Pharma

Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.

Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology.

The lead candidate HDP-101 (INN: pamlectabart tismanitin) is a BCMA ATAC in clinical development for multiple myeloma. The candidate has been granted Orphan Drug Designation and Fast Track Designation from the FDA. A second ATAC candidate, HDP-102 is in clinical development stage in Non-Hodgkin Lymphoma. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. Heidelberg Pharma is open for partnering.

The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com

ATAC^® is a registered trademark of Heidelberg Pharma Research GmbH.

Contact Heidelberg Pharma AG Sylvia Wimmer Director Corporate Communications Tel.: +49 89 41 31 38-29 E-Mail: investors@hdpharma.com Gregor-Mendel-Str. 22, 68526 Ladenburg	IR/PR-Support MC Services AG Katja Arnold (CIRO) Managing Director & Partner Tel.: +49 89 210 228-40 E-Mail: katja.arnold@mc-services.eu
International IR/PR-Support Optimum Strategic Communications Mary Clark, Zoe Bolt, Aoife Minihan Tel: +44 20 3882 9621 Email: HeidelbergPharma@optimumcomms.com

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Ad hoc announcement pursuant to Art. 53 LR

SKAN will miss sales and profit expectations for 2025 – order intake and backlog are developing very positively and laying a strong foundation for 2026

Allschwil, November 6, 2025 – The SKAN Group conducted a planned review of its project portfolio in the last days. This assessment identified delays in several projects that will affect sales and earnings in the current financial year. The SKAN Group will therefore not meet its sales and profit expectations for 2025. Order intake continues to develop very positively and lays the foundation for a strong 2026 financial year, which will be significantly above 2024 and 2025. The medium-term targets are confirmed.

The SKAN Group now expects net sales for the 2025 financial year to decline by a high single-digit percentage compared to the previous year. The EBITDA margin for 2025 is expected to be in the low double-digit range. This is significantly below the guidance for 2025, which had targeted net sales growth in the mid-single-digit range and an EBITDA margin between 14% and 16%.

The reason for this is that additional projects have been postponed since the summer, pushing significant portions of the highest turnover month of December into 2026. As a result of the lost sales, this year’s EBITDA is correspondingly lower.

The SKAN Group’s order intake continues to develop very positively in the current financial year, with particular demand for filling lines for oncology applications and biotechnologically produced injectable large molecules. It is already foreseeable that the order backlog will very likely reach a new high by the end of the year. This provides a strong basis for a successful 2026 financial year.

The medium- and long-term growth prospects for the SKAN Group remain positive, supported by structural market growth, a strong global competitive position, and a solid project pipeline. SKAN is therefore confirming its medium-term targets: It expects net sales to grow at an annual rate in the mid- to upper teens. The EBITDA margin is to be gradually increased to the upper teens in the mid-term, with potential for further increase beyond the mid-term period.

 

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

24 March 2026	Publication Annual Results 2025
7 May 2026	Annual General Meeting 2026

 

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs close to 1700 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, France, Slovenia, Croatia, Japan, the USA and Brazil.

 

Frauenfeld, 6 November 2025

Press release

DocMorris announces the start of the tender offer period for its Outstanding Convertible Bonds due 2026

After publication of the Offer Notice on 22 October 2025 and the end of the cooling-off period, DocMorris announces the start of the tender offer period for its Outstanding Convertible Bonds due 2026. The Tender Offer price for each of the Outstanding Convertible Bonds due 2026 amounts to CHF 1,035 per bond, corresponding to 103.50% of the par value, plus accrued and unpaid interest.

The tender offer period starts today and is expected to expire on 12 November 2025 at 4:00pm CET. Settlement of the Tender Offer is expected to occur on 17 November 2025. The bonds are listed and traded on SIX Swiss Exchange (ISIN: CH1210198169; SSN: A3K86S).

This press release is not an offer for the repurchase of the Outstanding Convertible Bonds due 2026 but only discloses the most important terms of the planned Tender Offer. The Tender Offer is solely made based on the Tender Offer notice published on 22 October 2025 in accordance with Swiss Tender Offer rules.

 

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

20 January 2026	Full-year 2025 revenue
19 March 2026	Full-year 2025 results and outlook 2026 (conference call/webcast)
16 April 2026	Q1/2026 Trading update
12 May 2026	Annual General Meeting, Zurich

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 5,000 physicians. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers in 2024. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

 

Disclaimer

THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE RESPONSIBILITY OF DOCMORRIS AG (THE “COMPANY”) AND DOCMORRIS FINANCE B.V. (THE “ISSUER”). THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.

THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES TO ANY PERSON IN THE UNITED STATES, AUSTRALIA, CANADA, ITALY, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW.

THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION. SECURITIES OF THE COMPANY OR THE ISSUER ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF THE COMPANY AND THE ISSUER REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE US SECURITIES ACT OF 1933 (THE “SECURITIES ACT”) OR OFFERED IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN “OFFSHORE TRANSACTION” IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT OR FOR THE ACCOUNT OR BENEFIT OF ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO THE SWISS FEDERAL ACT ON FINANCIAL SERVICES.

IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM (EACH, A “RELEVANT STATE”), THIS ANNOUNCEMENT AND ANY OFFER IF MADE SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE “QUALIFIED INVESTORS” WITHIN THE MEANING OF THE PROSPECTUS REGULATION (REGULATION (EU) 2017/1129) (“QUALIFIED INVESTORS”). IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE “ORDER”) OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED, AND ANY INVESTMENT ACTIVITY TO WHICH IT RELATES WILL ONLY BE ENGAGED IN WITH SUCH PERSONS AND IT SHOULD NOT BE RELIED ON BY ANYONE OTHER THAN SUCH PERSONS.

THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE, “FORWARD-LOOKING STATEMENTS”. THESE FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS “BELIEVES”, “ESTIMATES”, “PLANS”, “PROJECTS”, “ANTICIPATES”, “EXPECTS”, “INTENDS”, “MAY”, “WILL” OR “SHOULD” OR, IN EACH CASE, THEIR NEGATIVE OR OTHER VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS, OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING STATEMENTS MAY AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY FORWARD-LOOKING STATEMENTS REFLECT THE ISSUER’S OR THE COMPANY’S CURRENT VIEW WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS RELATING TO FUTURE EVENTS AND OTHER RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE GROUP’S BUSINESS, RESULTS OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY, PROSPECTS, GROWTH OR STRATEGIES. FORWARD-LOOKING STATEMENTS SPEAK ONLY AS OF THE DATE THEY ARE MADE. EACH OF THE ISSUER, THE COMPANY, THE JOINT BOOKRUNNERS AND THEIR RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY FORWARD LOOKING STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.

THIS PUBLICATION CONSTITUTES NEITHER A PROSPECTUS OR A SIMILAR COMMUNICATION WITHIN THE MEANING OF THE ARTICLES 35 ET SEQQ. AND 69 OF THE SWISS FINANCIAL SERVICES ACT OR UNDER ANY OTHER LAW OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE APPLICABLE LISTING RULES OF ANY STOCK EXCHANGE. ANY PURCHASE OF SHARES OF THE COMPANY IN THE PROPOSED OFFERING SHOULD BE MADE SOLELY ON THE BASIS OF PUBLICLY AVAILABLE INFORMATION. THE INFORMATION IN THIS ANNOUNCEMENT IS SUBJECT TO CHANGE. THE JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR ISSUER AND THE COMPANY AND NO-ONE ELSE IN CONNECTION WITH THE OFFERING. THEY WILL NOT REGARD ANY OTHER PERSON AS THEIR RESPECTIVE CLIENTS IN RELATION TO THE OFFERING AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN ISSUER AND THE COMPANY FOR PROVIDING THE PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS, NOR FOR PROVIDING ADVICE IN RELATION TO THE OFFERING, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO HEREIN.

THE JOINT BOOKRUNNERS, AND ANY OF THEIR AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS (INCLUDING SWAPS, WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH INVESTORS IN CONNECTION WITH WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SECURITIES OF THE ISSUER OR THE COMPANY. THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATIONS TO DO SO.

NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY RESPONSIBILITY OR LIABILITY WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO THE TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN THIS ANNOUNCEMENT (OR WHETHER ANY INFORMATION HAS BEEN OMITTED FROM THE ANNOUNCEMENT) OR ANY OTHER INFORMATION RELATING TO THE ISSUER OR THE COMPANY, THEIR SUBSIDIARIES OR ASSOCIATED COMPANIES, WHETHER WRITTEN, ORAL OR IN A VISUAL OR ELECTRONIC FORM, AND HOWSOEVER TRANSMITTED OR MADE AVAILABLE OR FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION THEREWITH.

NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER TO ACQUIRE SECURITIES IN ANY JURISDICTION. ANY INVESTOR SHOULD MAKE HIS INVESTMENT DECISION FOR THE PURCHASE OF THE SHARES ON PUBLICLY AVAILABLE INFORMATION.

 

The Supervisory Board of SCHOTT Pharma Management AG has today appointed Christian Mias as the new Chief Executive Officer (CEO) of SCHOTT Pharma, effective May 1, 2026. He will succeed Andreas Reisse, who will retire as planned at the end of April 2026. Christian Mias has held various management positions within the SCHOTT Group since 2007, most recently serving as Head of the Business Unit Electronic Packaging.
 

SCHOTT Pharma: Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma

• Andreas Reisse to retire as CEO of SCHOTT Pharma as planned
• Christian Mias, Executive Vice President of SCHOTT’s Electronic Packaging Business Unit, appointed as new CEO of SCHOTT Pharma effective May 1^st, 2026
• Seamless leadership transition ensured

The Supervisory Board of SCHOTT Pharma Management AG has appointed Christian Mias as CEO of SCHOTT Pharma. He will take over from Andreas Reisse, who will retire as planned in April 2026. Reisse will actively support a seamless leadership transition over the coming months to ensure continuity and stability for the company and the entire team.

Christian Mias, born in Iserlohn in 1974, will succeed Andreas Reisse starting May 1^st. As an industrial engineer with a doctoral degree, he looks back on more than 20 years of management experience, including over 18 years within the SCHOTT group. Before joining SCHOTT, he started his career as Commercial Project Manager at Siemens AG. Christian Mias gained significant experience in the pharmaceutical industry when joining SCHOTT Tubing, which produces intermediate products for the pharma sector, including SCHOTT Pharma. Throughout his career at SCHOTT, Christian has held leadership positions across various business units and continents, including roles as Managing Director in Brazil and Chief Operating Officer in the United States. In such roles, he successfully drove profitable growth by optimizing processes, improving productivity, and increasing earnings quality. Since 2016, he has served as Vice President, and since 2018 as Executive Vice President, currently heading the Business Unit Electronic Packing. Across his executive positions, Christian combined strategic foresight with operational discipline to drive the organizations toward consistent growth and strong financial performance.

Peter Goldschmidt, Chairman of the Supervisory Board of SCHOTT Pharma AG & Co. KGaA, said: “We are delighted to welcome Christian Mias as the new CEO of SCHOTT Pharma. His proven success within the SCHOTT Group, combined with strategic expertise and strong execution -demonstrated through integrative, performance-oriented, and participative leadership – makes him an excellent fit to lead SCHOTT Pharma into its next phase of profitable growth.

We are confident that Christian, together with Reinhard Mayer (CFO), will continue to drive profitable growth and further strengthen SCHOTT Pharma’s position as a global leader in pharmaceutical packaging and delivery systems.”

 

Commenting on his appointment, Christian Mias said: “I am honored to join SCHOTT Pharma at such an exciting time in the company’s journey. SCHOTT Pharma has built an exceptional reputation for innovation, quality, and reliability in the pharmaceutical industry. I look forward to working with the excellent team at SCHOTT Pharma to build upon this strong foundation and drive continued growth while advancing our mission to improve global healthcare. I would also like to thank Andreas Reisse for his outstanding leadership and dedication over the years. His vision and commitment have been instrumental in shaping SCHOTT Pharma’s success. I am looking forward to working together with Reinhard Mayer (CFO) on shaping the future of SCHOTT Pharma.”

 

Andreas Reisse has been with the SCHOTT Group since 1987 and has led the “Pharmaceutical Systems” division since 2010, which has been listed on the Frankfurt Stock Exchange as SCHOTT Pharma AG & Co. KGaA since 2023. He is now retiring upon reaching the statutory age limit for members of the Executive Board.

“Andreas Reisse has played an indispensable role in developing SCHOTT Pharma into one of the world’s leading companies in pharmaceutical containment solutions and delivery systems. Under his leadership, the company has achieved remarkable growth, delivered industry-leading innovations, and successfully transitioned to a publicly listed company. We thank him for his exceptional contributions and wish him all the best for his well-deserved retirement,” said Peter Goldschmidt.

Andreas Reisse commented: “It has been a privilege to spend so many years at SCHOTT Pharma and within the SCHOTT Group. I am very grateful for the collaboration and trust I have had with all stakeholders and the Supervisory Board. Together with a dedicated management team, we have established SCHOTT Pharma as a key partner in the pharmaceutical industry and achieved significant milestones, such as the successful IPO. As I prepare for retirement, I am confident that the company is well positioned for continued success and innovation. SCHOTT Pharma will be in excellent hands with Christian Mias, whom I have known and appreciated for almost two decades.”

For further news about SCHOTT Pharma, please visit our Media Center.

 

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com.   

Contact

Katrin Schreyer

Corporate Communications

Tel.: +49 (0) 6131 66-4932

E-Mail: katrin.schreyer@schott.com 

 

Lea Kaiser

Media Relations

Tel.: +49 (0) 6131 66-2422

E-Mail: lea.kaiser@schott.com 

 

Tobias Erfurth

Head of Investor Relations

E-Mail: Tobias.Erfurth@schott.com

 

Jasko Terzic, CFA

Senior Manager Investor Relations

E-Mail: Jasko.Terzic@schott.com

 

 

 

 

 

Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment (“D&PD”, (12.3)%) still sees soft demand; Just – Evotec Biologics (“JEB”; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business Strong scientific advancements of co-developed asset pipeline: Expecting up to four molecules in clinical phase II in next six to nine months Signing of landmark industry transaction with Sandoz on 04 November, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules 2025 guidance and 2028 outlook confirmed

Hamburg, Germany, 05 November 2025:

Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced its business update for 9M 2025, illustrating the ongoing systematic execution of its strategy. In the D&PD segment, the market for early drug discovery services remained soft, while strategic partnerships are on track and Evotec records strong progress in its partnered asset pipeline. JEB continues its strong momentum and reports further accelerating growth in the non-Sandoz / non-DoD business.

After the end of the period, Evotec signed a > US$ 650 m landmark transaction with Sandoz AG (SIX:SDZ/OTCQX:SDZNY) on 04 November. According to the terms of the agreement, Sandoz will acquire 100% of Just – Evotec Biologics EU in Toulouse plus an indefinite technology license to Evotec’s continuous manufacturing platform technology for a payment of approximately US$ 350 m in cash. The agreement includes additional license fees and development revenues including success-based milestones, adding up to more than US$ 300 m in the coming years, replacing existing contractual commitments. In the future, Evotec expects to benefit from royalties on a portfolio of up to ten biosimilars in technical and early development, targeting a net-originator sales market of more than US$ 90 bn.

Dr Christian Wojczewski, Chief Executive Officer of Evotec:

“Evotec remains firmly on track in delivering against its strategic objectives, demonstrating strong execution for future sustainable and profitable growth. Despite a continued softness in the early drug discovery market, we are seeing first signals of improvement in our base business in D&PD. With 11% revenue growth year-over-year, JEB is not only enjoying high demand but also delivering strong results above our expectations. The agreement with Sandoz enables us to sharpen our focus on JEB’s capabilities as a scalable technology provider with an asset-lighter model. The transaction is a testament for our world class continuous manufacturing technology. A core element of our new strategy is to sharpen our offering and reduce complexity while progress in our strategic partnerships continues to build momentum.“
 

Continuing challenges for D&PD; JEB building strong momentum

• Group revenues decrease by (7.1)% to € 535.1 m (9M 2024: € 575.7 m)
• Total D&PD revenues decrease by (12.3)% to € 392.1 m (9M 2024: € 447.1 m), due to soft demand in the early drug discovery service market; quotations are growing in number and value, negative change orders are declining
• JEB revenues increase by 11.3% to € 143.4 m (9M 2024: € 129.3 m), driven by continued strong non-Sandoz / non-Department of Defense (“DoD”) business growth of 105% year over year
• Adjusted Group EBITDA totaled € (16.9) m (9M 2024: € (6.0) m) driven by continued underutilization and a high fixed cost base in the D&PD segment as well as costs related to the ramp-up of the JEB Toulouse facility
• Cost out initiatives ahead of plan, expected to result in a total cost reduction of more than € 60 m in 2025 (2x initial target)
   

Driving growth through strategic priorities

• Significant progress in the strategic protein degradation collaboration with Bristol Myers Squibb (“BMS”) resulted in performance- and program-based payments amounting to US$ 75 m the first half of the year
• In the second quarter, Evotec reported key advancements in its neuroscience collaboration with BMS, resulting in a US$ 20 m research payment to the company
• Two partnered assets entered Phase II clinical trials
   

Events after Period-End

• In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments of potentially over US$ 650 m plus royalties on a portfolio of up to 10 biosimilar molecules
• Progress in the strategic preclinical neuroscience partnership with BMS resulted in a payment of US$25m to support the continued progression of joint programs
• Investigational New Drug (“IND”) submission by partner Dewpoint Therapeutics for novel oncology therapy marks culmination of the partnership, advancing a de novo development candidate from discovery through IND-enabling studies
• Evotec’s collaboration with Esperion leads to the nomination of a preclinical development candidate for the treatment of Primary Sclerosing Cholangitis, a chronic, progressive disease-causing inflammation and sclerosis of the bile ducts leading over time to liver cell damage and can result in fibrosis, cirrhosis, and eventually liver failure
   

Guidance for full-year 2025 confirmed

• Group revenues expected in the range of € 760 – 800 m (2024: € 797.0 m)
• R&D expenditures are expected in a range of € 40 – 50 m (2024: € 50.9 m)
• Adjusted Group EBITDA is expected to reach € 30 – 50 m (2024: € 22.6 m)
   

Outlook 2028

• Group revenues CAGR _2024-2028 targeted to be in a range of 8 – 12%
• Adjusted EBITDA margin 2028 expected to be above 20%

More detailed information and financial tables are available in the interim statement for the first nine months 2025 published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/financial-publications

 

Webcast/Conference Call

The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.

Webcast details

Date:  Wednesday, 05 November 2025

Time:  2.00 pm CET (01.00 pm GMT, 08.00 am EST)

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand version of the webcast will be available on our website: Financial Publications – Evotec.

Conference call details

To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialling in via phone is available

 

About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

 

For further information, please contact:

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com